Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2021.2024940
Abstract: ABSTRACT Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods:… read more here.
Keywords: myeloid leukemia; aml; latin america; acute myeloid ... See more keywords
Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
Sign Up to like & getrecommendations! Published in 2024 at "Hematology"
DOI: 10.1080/16078454.2024.2418653
Abstract: ABSTRACT Background: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological… read more here.
Keywords: myeloid malignancies; venetoclax based; allo hsct; based regimens ... See more keywords
Monocentric experience of venetoclax‐based regimen in paediatric refractory and relapsed AML/MDS
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Haematology"
DOI: 10.1111/bjh.19849
Abstract: BCL‐2 inhibitor venetoclax demonstrates promising efficacy in paediatric relapsed/refractory acute myeloid leukaemia (r/r AML). This retrospective analysis evaluated 12 patients treated with venetoclax‐based regimens under compassionate use for r/r myeloid malignancies. The overall response rate… read more here.
Keywords: venetoclax based; based regimen; monocentric experience; regimen paediatric ... See more keywords
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Haematology"
DOI: 10.1111/ejh.14290
Abstract: Elderly acute myeloid leukemia (AML) patients with poor‐risk cytogenetics have a poor outcome with intensive chemotherapy (IC). While Venetoclax (VEN) has changed the outcomes of elderly unfit patients treatment, it is unknown whether it could… read more here.
Keywords: venetoclax based; elderly acute; myeloid leukemia; acute myeloid ... See more keywords
Abstract 4357893: Cardiovascular Adverse Events with Venetoclax-Based Treatment in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2025 at "Circulation"
DOI: 10.1161/circ.152.suppl_3.4357893
Abstract: Introduction: Venetoclax, a BCL-2 antagonist, is a novel anti-neoplastic agent used in various hematologic malignancies, including acute myeloid leukemia (AML). The aim of the current study is to evaluate the incidence, risk factors, and outcome… read more here.
Keywords: treatment; venetoclax based; acute myeloid; risk ... See more keywords
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207231155028
Abstract: Background: Patients with relapsed/refractory multiple myeloma (RRMM) usually have dismal prognostic outcomes. Venetoclax, a selective inhibitor of antiapoptotic protein B-cell lymphoma-2 (BCL-2), demonstrates antimyeloma activity in plasma cells with t(11;14) or high BCL-2 expression. Objectives:… read more here.
Keywords: safety; meta analysis; relapsed refractory; analysis ... See more keywords
First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139923
Abstract: Background: The outcome of elderly patients with Acute Myeloid Leukemia (AML) is poor and treatment options in these high-risk groups are limited. Recently, venetoclax combinations with hypomethylating agents or low dose cytarabine were approved to… read more here.
Keywords: consultancy honoraria; venetoclax based; abbvie inc; research funding ... See more keywords
Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1499
Abstract: Introduction Acute myeloid leukemia(AML) is a heterogeneous malignancy marked by impaired myeloid differentiation and resistance to apoptosis. Venetoclax, a selective BCL-2 inhibitor that restores apoptotic signaling, has shown improved outcomes when combined with hypomethylating agents… read more here.
Keywords: mdp; venetoclax based; cell; based therapy ... See more keywords
Palliative care for AML patients on venetoclax-based therapy: A single-center real-world study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2830
Abstract: Background: Randomized trials demonstrate that patients with AML hospitalized for intensive chemotherapy benefit significantly from early integrated palliative care (PC), yielding improvements in quality of life (QOL) and end of life (EOL) care (El-Jawahri, JAMA… read more here.
Keywords: received less; venetoclax based; aml; care ... See more keywords
Early and safe administration of G-CSF in AML patients treated with venetoclax-based therpy: Clinical and molecular insights from a single czech center
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6906
Abstract: Introduction: This analysis evaluates the impact of early administration of the growth factor G-CSF during the first therapy cycle in 117 patients with acute myeloid leukemia (AML) treated with venetoclax-based combination therapy. Not only were… read more here.
Keywords: treatment; venetoclax based; salvage; response ... See more keywords
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2023019634
Abstract: Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT) while their prognostic impact in the context of venetoclax-based treatments is still debated. In this prospective analysis on… read more here.
Keywords: cll treated; venetoclax based; complexity; complex karyotypes ... See more keywords